Sarepta Therapeutics Inc  

(Public, NASDAQ:SRPT)   Watch this stock  
Find more results for NASDAQ:AVII
30.00
+0.25 (0.84%)
Real-time:   3:00PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.38 - 30.43
52 week 11.33 - 33.16
Open 29.69
Vol / Avg. 470,814.00/2.26M
Mkt cap 1.23B
P/E     -
Div/yield     -
EPS -4.13
Shares 41.47M
Beta 1.12
Inst. own 60%
Aug 5, 2015
Q2 2015 Sarepta Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 2, 2015
Sarepta Therapeutics Inc Annual Shareholders Meeting
May 7, 2015
Q1 2015 Sarepta Therapeutics Inc Earnings Release
May 7, 2015
Q1 2015 Sarepta Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -1391.71%
Operating margin - -1371.21%
EBITD margin - -1313.34%
Return on average assets -91.83% -46.30%
Return on average equity -110.13% -54.88%
Employees 204 -
CDP Score - -

Address

SUITE 415, 215 FIRST STREET
CAMBRIDGE, MA 02142
United States - Map
+1-617-2744000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

Officers and directors

Edward M. Kaye M.D. Interim Chief Executive Officer, Senior Vice President, Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Sandesh Mahatme Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
David Tyronne Howton Senior Vice President, General Counsel, Corporate Secretary
Age: 43
Bio & Compensation  - Reuters
Jayant Aphale Ph.D. Senior Vice President - Technical Operations
Age: 54
Bio & Compensation  - Reuters
M. Kathleen Behrens Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Anthony R. Chase Independent Director
Age: 60
Bio & Compensation  - Reuters
Gil Price M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Hans Wigzell M.D., Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
William A. Goolsbee Non-Executive Independent Director
Age: 61
Bio & Compensation  - Reuters